Last reviewed: May 24, 2026
Last updated: May 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Four GLP-1 receptor agonists are FDA-approved for chronic weight management: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda), and dulaglutide (Trulicity). Tirzepatide demonstrated the highest mean weight loss at 21.4% of baseline body weight over 72 weeks in SUMO trials.
Weight loss medication selection is not one-size-fits-all. Patient genetics, baseline metabolic markers, comorbidities, and GLP-1 receptor pathway variations influence how individuals may respond. PlexusDx supports precision conversations between patients and providers by contextualizing approved options with personalized biomarker and genetic data.
FDA-Approved GLP-1 Agonists: Approval Timeline and Mechanism
Semaglutide (Wegovy) received FDA approval for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023. Both work by stimulating GLP-1 receptors in the hypothalamus to increase satiety and reduce hunger signals. Liraglutide (Saxenda) and dulaglutide (Trulicity) were approved earlier but with more modest efficacy.
Each medication binds to GLP-1 receptors with slightly different affinities and tissue distribution patterns. Tirzepatide, a dual GIP/GLP-1 agonist, activates both GLP-1 and glucose-dependent insulinotropic peptide (GIP) pathways, which may explain its superior weight loss outcomes in clinical trials.
Comparative Clinical Efficacy and Trial Outcomes
Randomized controlled trials provide objective benchmarks for each approved agent. Mean weight loss varies significantly by medication, baseline BMI, and treatment duration. Below is a summary of pivotal trial data across approved GLP-1 agents for weight loss.
| Medication |
Trial Name |
Duration |
Mean Weight Loss |
Key Population |
| Tirzepatide (Zepbound) |
SUMO-4 |
72 weeks |
21.4% of baseline |
BMI ≥27 with ≥1 comorbidity |
| Semaglutide (Wegovy) |
STEP-4 |
68 weeks |
17.4% of baseline |
BMI ≥30 or ≥27 with comorbidity |
| Liraglutide (Saxenda) |
SCALE |
56 weeks |
8.4% of baseline |
BMI ≥30 or ≥27 with comorbidity |
| Dulaglutide (Trulicity) |
REWIND |
104 weeks |
2.5 kg (post-hoc) |
Type 2 diabetes, secondary indication |
Patient Selection and Metabolic Biomarker Context
FDA approval requires BMI ≥ 30 kg/m² or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, obstructive sleep apnea). Baseline fasting glucose, insulin resistance markers, and lipid profiles may provide additional context for medication selection and expected metabolic benefits.
Patients with impaired fasting glucose or prediabetes may experience differential glucose-lowering effects depending on GLP-1 pathway activation patterns. Genetic variants in GLP1R, GIPR, and FTO genes may influence baseline metabolic state and individual response trajectories, though clinical response prediction remains complex.
Safety Considerations and Provider-Led Personalization
Common adverse effects include nausea, vomiting, diarrhea, and constipation; serious risks include acute pancreatitis, thyroid concerns, and gallbladder complications. Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. A qualified healthcare provider must assess individual safety profiles.
Compounded formulations sourced from licensed 503A pharmacies offer dosing flexibility and cost accessibility compared to branded options. Starting with lower doses allows for gradual titration and improved tolerability. Genetic predisposition testing may help contextualize individual metabolic baseline and support a more informed conversation with your provider about which approved agent aligns with your health profile.
How PlexusDx Supports a More Personalized Approach
PlexusDx Precision Peptide Genetic Test may help provide context regarding your genetic predispositions in peptide and metabolic pathways. Key variants in GLP1R (rs6923761) and GIPR (rs1800437) influence receptor expression and signaling efficiency. These predispositions should be interpreted with a qualified healthcare provider as part of a comprehensive clinical assessment.
The genetic test reveals how your inherited variants may influence baseline metabolic state and GLP-1 pathway function. However, genetics alone do not predict exact medication response; environmental factors, diet, exercise, comorbidities, and medication interactions significantly influence real-world outcomes. Genetic data can support a more personalized conversation, not replace medical evaluation.
Understanding your genetic predispositions in GLP-1 and GIP receptor pathways, combined with biomarker assessment and clinical history, can help your healthcare provider select the FDA-approved GLP-1 agent most likely to align with your unique metabolic profile and treatment goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Tirzepatide Dose Adjustment Signs & Biomarker Context
When Will I See Weight Loss on Tirzepatide? Timeline & Factors